drug affinity complex raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-08-23. Anything still debated is marked as such rather than presented as settled.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.
Batch-to-batch consistency depends on solid-phase peptide synthesis and subsequent purification. Coupling efficiency, resin choice, and cleavage conditions all affect the final profile. Counter-ion content and moisture can shift the apparent mass of a batch. Documentation typically includes a certificate of analysis with chromatograms and spectra. Independent verification by a second laboratory is sometimes requested. Whether a given certificate reflects the actual vial contents depends on chain of custody. Analytical methods themselves carry uncertainty that should be stated alongside results.
Lyophilized material is typically stored at minus twenty degrees Celsius or lower. Keeping the vial dry and protected from light preserves peptide integrity. Repeated freeze-thaw cycles can cause aggregation or loss of activity. Once dissolved, solutions are generally kept at two to eight degrees Celsius. Stability data for reconstituted solutions vary, and long-term behavior is not fully established. Working aliquots reduce the number of times a stock container is opened.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C152H252N44O42 | Cited for the form without the drug affinity complex |
| Molecular weight | About 3368 Da | Reported value for modified GRF(1-29) |
| Appearance | White to off-white powder | Lyophilised solid as usually supplied |
| Solubility | Soluble in water and polar solvents | Clarity depends on purity and salt content |
| Typical storage | -20 C or below, dry | Protect from light and repeated warming cycles |
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
Pre-existing acute or chronic liver dysfunction or family history of severe liver inflammation (hepatitis), particularly medicine related. Pregnancy 11% risk of birth defects and 30-40% risk of neuro-developmental disabilities which can be permanent Known hypersensitivity to valproate or any of the ingredients used in the preparation Urea cycle disorders Hepatic porphyria Hepatotoxicity Mitochondrial disease Pancreatitis Porphyria
=== Food products === In 1909, Ajinomoto Co. Inc. released its umami seasoning AJI-NO-MOTO, made from molasses and tapioca starch derived from sugarcane. In Asia and Latin America, the product was primarily sold to consumers, while in North America and Europe it was mostly sold to processed food manufacturers. In 1970, Ajinomoto launched the bonito flavored seasoning HON-DASHI in Japan, and later adapted the product to other markets with local flavors. In 1978 Ajinomoto released Cook Do, a series of Chinese cuisine seasoning products, and later added other cuisine seasoning flavors to the Cook Do product line. The company entered the frozen food business in 1972, and currently sells a variety of frozen food products, including dumplings, noodles, and cooked rice. In 1982, Ajinomoto Co., Inc. entered the sweetener business by producing aspartame. In 1984 it released a low-calorie consumer sweetener PAL SWEET. By 2021, Ajinomoto was ranked 6th overall and 1st in Asia on FoodTalks' Top 50 Global Sweetener Companies list. Ajinomoto Co., Inc. is the world's largest manufacturer of aspartame, sold under the trade name Aminosweet. Ajinomoto also sells soup, mayonnaise, porridge, pasta sauce, and instant noodles under the "VONO" brand name. Through Ajinomoto AGF Corporation, Ajinomoto sells instant coffee, regular coffee, bottled coffee, stick coffee, and canned coffee, and is the top coffee brand in Thailand with a 70% market share. Ajinomoto's Yum Yum brand of instant noodles in 2019 held a 20–21% share of Thailand's 17 billion baht instant noodle market.
In 1978 he had established a Women's Military Academy in Tripoli, encouraging all women to enlist for training. The measure was hugely controversial and voted down by the GPC in February 1983. Gaddafi remained adamant, and when it was again voted down by the GPC in March 1984, he refused to abide by the decision, declaring that "he who opposes the training and emancipation of women is an agent of imperialism, whether he likes it or not." The Jamahiriya's radical direction earned the government many enemies. Most internal opposition came from Islamic fundamentalists, inspired by the events of the 1979 Iranian Revolution. In February 1978, Gaddafi discovered that his head of military intelligence was plotting to kill him and increasingly entrusted security to his Qadhadfa tribe. Many who had seen their wealth confiscated turned against the administration, and Western-funded opposition groups were founded by exiles. Most prominent was the National Front for the Salvation of Libya (NFSL), which orchestrated militant attacks against Libya's government. Another, al-Borkan, began killing Libyan diplomats abroad. Following Gaddafi's command to kill these "stray dogs", the Revolutionary Committees set up overseas branches to suppress counter-revolutionary activity, assassinating dissidents. Although Syria and Israel also employed hit squads, Gaddafi was unusual in publicly bragging about his use of them; in April 1980, he ordered all dissidents to return home by 10 June or be "liquidated wherever you are".
== J == Sophie E. Jackson (active from 1991). Biochemist at the University of Cambridge known for work on protein folding. Alec Jeffreys FRS (b. 1950). British biochemist and geneticist at Leicester University, known for inventing genetic fingerprinting. William Jencks FRS (foreign member) (1927–2007). American biochemist at Brandeis University, known for applying chemical mechanisms to enzyme-catalysed reactions and for his masterly book Catalysis in Chemistry and Enzymology. Member Natl. Acad. Sci. USA. Thomas H. Jukes (1906–1999). British-American biologist at UC Berkeley known for work in nutrition and molecular evolution. He was very active in denouncing pseudoscience. John Michael Jumper (b. 1985). American chemist and computer scientist at DeepMind Technologies. Nobel Prize in chemistry, 2024.
Sources: en.wikipedia.org
Premier League: 1997–98, 2001–02, 2003–04 FA Cup: 1997–98, 2001–02, 2002–03, 2004–05, 2013–14, 2014–15, 2016–17; runner-up: 2000–01 FA Charity/Community Shield: 1998, 1999, 2002, 2004, 2014, 2015 2017 Football League/EFL Cup runner-up: 2006–07, 2010–11, 2017–18 UEFA Champions League runner-up: 2005–06 UEFA Cup runner-up: 1999–2000 Individual
=== Mineral resources === Ningxia is rich in mineral resources with proven deposits of 34 kinds of minerals, much of which located in grassland areas. In 2011 it was estimated that the potential value per capita of these resources accounted for 163.5 percent of the nation's average. Ningxia boasts verified coal reserves of over 30 billion tons, with an estimated reserve of more than 202 billion tons, ranking sixth nationwide. Coal deposits are spread over one-third of the total surface of Ningxia, and mined in four major fields in the Helan and Xiangshan mountains, Ningdong and Yuanzhou (or Guyuan). The region's reserves of oil and natural gas can be found in Yanchi and Lingwu County, and are ideal for large-scale development of oil, natural gas and chemical industries. Ningxia leads China in gypsum deposits, with a proven reserve of more than 4.5 billion tons, of which the rarely found, top-grade gypsum accounts for half of the total deposits. The Hejiakouzi deposit in Tongxin County features a reserve of 20 million tons of gypsum with a total thickness of 100 meters. There is a considerable deposit of quartz sandstone, of which 17 million tons have been ascertained. In addition, there are phosphorus, flint, copper, iron, barite, other minerals and Helan stone – a special clay stone.
2.A.1 Major Facilitator superfamily (MFS), see also Lactose permease, Phosphate permease and Glucose transporter 2.A.2 The Glycoside-Pentoside-Hexuronide (GPH):Cation Symporter Family 2.A.3 The Amino Acid-Polyamine-Organocation (APC) Family 2.A.4 Cation diffusion facilitator (CDF) Family 2.A.5 Zinc (Zn2+)-Iron (Fe2+) Permease Family 2.A.6 Resistance-Nodulation-Cell Division Superfamily, see also SecDF protein-export membrane protein 2.A.7 The Drug/Metabolite Transporter (DMT) Superfamily 2.A.8 The Gluconate:H+ Symporter (GntP) Family 2.A.9 The Membrane Protein Insertase (YidC/Alb3/Oxa1) Family 2.A.10 The 2-Keto-3-Deoxygluconate Transporter (KdgT) Family 2.A.11 The Citrate-Mg2+:H+ (CitM) Citrate-Ca2+:H+ (CitH) Symporter (CitMHS) Family 2.A.12 ATP:ADP Antiporter Family 2.A.13 The C4-Dicarboxylate Uptake (Dcu) Family 2.A.14 Lactate Permease Family 2.A.15 The Betaine/Carnitine/Choline Transporter (BCCT) Family 2.A.16 Tellurite-resistance/Dicarboxylate Transporter Family 2.A.17 Proton-dependent Oligopeptide Transporter Family 2.A.18 The Amino Acid/Auxin Permease (AAAP) Family 2.A.19 The Ca2+:Cation Antiporter (CaCA) Family 2.A.20 The Inorganic Phosphate Transporter (PiT) Family 2.A.21 Solute:Sodium Symporter Family 2.A.22 The Neurotransmitter:Sodium Symporter Family 2.A.23 The Dicarboxylate/Amino Acid:Cation (Na+ or H+) Symporter (DAACS) Family 2.A.24 The 2-Hydroxycarboxylate Transporter (2-HCT) Family 2.A.25 Alanine or Glycine:Cation Symporter (AGCS) Family 2.A.26 The Branched Chain Amino Acid:Cation Symporter (LIVCS) Family 2.A.27 The Glutamate:Na+ Symporter (ESS) Family 2.A.28 Bile Acid:Na+ Symporter Family 2.A.29 Mitochondrial carrier Family 2.A.30 Cation-Chloride Cotransporter (CCC) Family 2.A.31 Anion Exchanger Family 2.A.32 The Silicon Transporter (Sit) Family 2.A.33 NhaA Na+:H+ Antiporter (NhaA) Family 2.A.34 The NhaB Na+:H+ Antiporter (NhaB) Family 2.A.35 The NhaC Na+:H+ Antiporter (NhaC) Family 2.A.36 Monovalent Cation:Proton Antiporter-1 (CPA1) Family 2.A.37 Monovalent Cation:Proton Antiporter-2 (CPA2) Family 2.A.38 K+ Transporter (Trk) Family 2.A.39 Nucleobase:Cation Symporter-1 (NCS1) Family 2.A.40 Nucleobase:Cation Symporter-2 (NCS2) Family 2.A.41 The Concentrative Nucleoside Transporter (CNT) Family 2.A.42 The Hydroxy/Aromatic Amino Acid Permease (HAAAP) Family 2.A.43 The Lysosomal Cystine Transporter (LCT) Family 2.A.45 Arsenite-Antimonite Efflux Family 2.A.46 The Benzoate:H+ Symporter (BenE) Family 2.A.47 Divalent Anion:Na+ Symporter (DASS) Family 2.A.48 The Reduced Folate Carrier (RFC) Family 2.A.49 Chloride Carrier/Channel (ClC) Family 2.A.50 The Glycerol Uptake (GUP) Family 2.A.51 The Chromate Ion Transporter (CHR) Family 2.A.52 The Ni2+-Co2+ Transporter (NiCoT) Family 2.A.53 Sulfate permease (SulP) Family 2.A.54 The Mitochondrial Tricarboxylate Carrier (MTC) Family 2.A.55 The Metal Ion (Mn2+-iron) Transporter (Nramp) Family 2.A.56 The Tripartite ATP-independent Periplasmic Transporter (TRAP-T) Family 2.A.57 The Equilibrative Nucleoside Transporter (ENT) Family 2.A.58 The Phosphate:Na+ Symporter (PNaS) Family 2.A.59 The Arsenical Resistance-3 (ACR3) Family 2.A.60 Organo Anion Transporter (OAT) Family 2.A.61 The C4-dicarboxylate Uptake C (DcuC) Family 2.A.62 The NhaD Na+:H+ Antiporter (NhaD) Family 2.A.63 The Monovalent Cation (K+ or Na+):Proton Antiporter-3 (CPA3) Family 2.A.64 Twin Arginine Targeting (Tat) Family 2.A.65 The Bilirubin Transporter (BRT) Family 2.A.66 The Multidrug/Oligosaccharidyl-lipid/Polysaccharide (MOP) Flippase Superfamily 2.A.67 The Oligopeptide Transporter (OPT) Family 2.A.68 The p-Aminobenzoyl-glutamate Transporter (AbgT) Family 2.A.69 The Auxin Efflux Carrier (AEC) Family 2.A.70 The Malonate:Na+ Symporter (MSS) Family 2.A.71 The Folate-Biopterin Transporter (FBT) Family 2.A.72 The K+ Uptake Permease (KUP) Family 2.A.73 The Short Chain Fatty Acid Uptake (AtoE) Family 2.A.74 The 4 TMS Multidrug Endosomal Transporter (MET) Family 2.A.75 The L-Lysine Exporter (LysE) Family 2.A.76 The Resistance to Homoserine/Threonine (RhtB) Family 2.A.77 The Cadmium Resistance (CadD) Family 2.A.78 The Branched Chain Amino Acid Exporter (LIV-E) Family 2.A.79 The Threonine/Serine Exporter (ThrE) Family 2.A.80 The Tricarboxylate Transporter (TTT) Family 2.A.81 The Aspartate:Alanine Exchanger (AAEx) Family 2.A.82 The Organic Solute Transporter (OST) Family 2.A.83 The Na+-dependent Bicarbonate Transporter (SBT) Family 2.A.84 The Chloroplast Maltose Exporter (MEX) Family 2.A.85 The Aromatic Acid Exporter (ArAE) Family 2.A.86 The Autoinducer-2 Exporter (AI-2E) Family (Formerly the PerM Family, TC #9.B.22) 2.A.87 The Prokaryotic Riboflavin Transporter (P-RFT) Family 2.A.88 Vitamin Uptake Transporter (VUT or ECF) Family 2.A.89 The Vacuolar Iron Transporter (VIT) Family 2.A.90 Vitamin A Receptor/Transporter (STRA6) Family 2.A.91 Mitochondrial tRNA Import Complex (M-RIC) (Formerly 9.C.8) 2.A.92 The Choline Transporter-like (CTL) Family 2.A.94 The Phosphate Permease (Pho1) Family 2.A.95 The 6TMS Neutral Amino Acid Transporter (NAAT) Family 2.A.96 The Acetate Uptake Transporter (AceTr) Family 2.A.97 The Mitochondrial Inner Membrane K+/H+ and Ca2+/H+ Exchanger (LetM1) Family 2.A.98 The Putative Sulfate Exporter (PSE) Family 2.A.99 The 6TMS Ni2+ uptake transporter (HupE-UreJ) Family 2.A.100 The Ferroportin (Fpn) Family 2.A.101 The Malonate Uptake (MatC) Family (Formerly UIT1) 2.A.102 The 4-Toluene Sulfonate Uptake Permease (TSUP) Family 2.A.103 The Bacterial Murein Precursor Exporter (MPE) Family 2.A.104 The L-Alanine Exporter (AlaE) Family 2.A.105 The Mitochondrial Pyruvate Carrier (MPC) Family 2.A.106 The Ca2+:H+ Antiporter-2 (CaCA2) Family 2.A.107 The MntP Mn2+ Exporter (MntP) Family 2.A.108 The Iron/Lead Transporter (ILT) Family 2.A.109 The Tellurium Ion Resistance (TerC) Family 2.A.110 The Heme Transporter, heme-responsive gene protein (HRG) Family 2.A.111 The Na+/H+ Antiporter-E (NhaE) Family 2.A.112 The KX Blood-group Antigen (KXA) Family 2.A.113 The Nickel/cobalt Transporter (NicO) Family 2.A.114 The Putative Peptide Transporter Carbon Starvation CstA (CstA) Family 2.A.115 The Novobiocin Exporter (NbcE) Family 2.A.116 The Peptidoglycolipid Addressing Protein (GAP) Family 2.A.117 The Chlorhexadine Exporter (CHX) family 2.A.118 The Basic Amino Acid Antiporter (ArcD) Family 2.A.119 The Organo-Arsenical Exporter (ArsP) Family 2.A.120 The Putative Amino Acid Permease (PAAP) Family 2.A.121 The Sulfate Transporter (CysZ) Family 2.A.122 The LrgB/CidB holin-like auxiliary protein (LrgB/CidB) Family 2.A.123 The Sweet; PQ-loop; Saliva; MtN3 (Sweet) Family 2.A.124 The Lysine Exporter (LysO) Family 2.A.125 The Eukaryotic Riboflavin Transporter (E-RFT) Family 2.A.126 The Fatty Acid Exporter (FAX) Family 2.A.127 Enterobacterial Cardiolipin Transporter (CLT) Family
Sources: en.wikipedia.org
=== Effects === In general, MDMA users report feeling the onset of subjective effects within 30 to 60 minutes of oral consumption and reaching peak effect at 75 to 120 minutes, which then plateaus for about 3.5 hours. The desired short-term psychoactive effects of MDMA have been reported to include:
=== Partition coefficient === Study of the solubility data shows that bronopol has a high affinity for polar rather than non-polar environments. In two-phase systems, bronopol partitions preferentially into the polar (usually aqueous) phase.
=== Droplet merging === As an existing droplet can be split to form discrete droplets using electrodes (see From an existing droplet), droplets can be merged into one droplet by electrodes as well. Utilizing the same concept applied for creating new droplets through splitting an existing droplet with electrodes, an aqueous droplet resting on an uncharged electrode can move towards a charged electrode where droplets will join and merge into one droplet. However, the merged droplet might not always form a circular shape even after the merging process is over due to surface tension. This problem can be solved by implementing a superhydrophobic surface between the droplets and the electrodes. Oil droplets can be merged in the same way as well, but oil droplets will move towards uncharged electrodes unlike aqueous droplets.
(for the number of infected persons). The KdV-SIR equation shares the same form as the Korteweg–De Vries equation in the traveling wave coordinate. An analytical solution to the KdV-SIR equation is written as follows:
Sources: en.wikipedia.org
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.
No regulatory agency has approved CJC-1295 for clinical use. Human trials were conducted in the 2000s, but the development programme was discontinued before any marketing application succeeded. Material sold today is offered as a research chemical, and its purity depends on the supplier.
Sermorelin is an unmodified fragment of growth hormone-releasing hormone and is cleared quickly. CJC-1295 contains substitutions that resist breakdown, and the form with a drug affinity complex persists much longer. Both act at the same receptor but differ substantially in duration of action.
The powder is normally held at minus twenty degrees Celsius or below. Light and moisture exposure should be minimized. Repeated warming and cooling cycles are avoided.